Novavax: How the company’s protein-based vaccine works

American biotech company Novavax announced on June 14 its COVID-19 vaccine has proven more than 90 percent effective against variants in late-stage trials.

If approved, it would be the fourth COVID-19 vaccine available in the United States.

The study, which involved 30,000 volunteers in the U.S. and Mexico, puts the company’s inoculation on track to file for emergency authorization in the U.S.

The Maryland-based company said its protein-based COVID-19 vaccine was 93 percent effective against the easily transmissible coronavirus variants.

The vaccine was also found to be effective against a variant originally detected in the United Kingdom.

According to a company press release, Novavax intends to file for regulatory authorization in the third quarter, with plans to manufacture 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of this year.


Leave a comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.